The global Androgen Receptor Antagonist market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Androgen receptor (AR) is an important target of prostate cancer drugs, and its structure plays an important guiding role in drug development. The androgen receptor consists of 4 structural domains and 8 exons, which are N-terminal binding domain (NTD, exon 1), DNA binding domain (DBD, exon 2-3), hinge region ( HR, exon 4), C-terminal binding domain (LBD, exons 5-8), nuclear localization signal (NLS) is a dichotomous motif contained within exons 3 and 4. The LBD contains a buried hormone-binding pocket (HBP) and a transcriptional activation domain, AF2. AF2 plays an important role in the formation of homodimers, AF2 contains helices 3, 4, 5 and 12 (H3, H4, H5, H12), H12 can change position when ligand binds, when ligand binds to the binding pocket Upon binding, H12 folds back closer to the binding site, preventing ligand disengagement. Non-steroidal AR antagonists avoid the common hormone-like toxic side effects of steroidal AR antagonists, expand clinical applications, and are currently the most commonly used prostate cancer drugs in the United States.

United States market for Androgen Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Androgen Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Androgen Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Androgen Receptor Antagonist players cover Merck & Co., Inc, Sanofi, Astellas Pharma Inc, Pfizer, Johnson & Johnson, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

Infinity Market Research newest research report, the Androgen Receptor Antagonist Industry Forecast looks at past sales and reviews total world Androgen Receptor Antagonist sales in 2024, providing a comprehensive analysis by region and market sector of projected Androgen Receptor Antagonist sales for 2025 through 2031. With Androgen Receptor Antagonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Androgen Receptor Antagonist industry.

This Insight Report provides a comprehensive analysis of the global Androgen Receptor Antagonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Androgen Receptor Antagonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Androgen Receptor Antagonist market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Androgen Receptor Antagonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Androgen Receptor Antagonist.

This report presents a comprehensive overview, market shares, and growth opportunities of Androgen Receptor Antagonist market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    First Generation Inhibitors
    Second Generation Inhibitors

Segmentation by Application:

    Prostate Cancer
    Breast Cancer
    Other

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Merck & Co., Inc
    Sanofi
    Astellas Pharma Inc
    Pfizer
    Johnson & Johnson
    Bayer
    Hinova
    Jiangsu Hengrui Pharmaceuticals Co., Ltd
    Kintor Pharma

Key Questions Addressed in this Report

What is the 10-year outlook for the global Androgen Receptor Antagonist market?
What factors are driving Androgen Receptor Antagonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Androgen Receptor Antagonist market opportunities vary by end market size?
How does Androgen Receptor Antagonist break out by Type, by Application?